dipyridamole has been researched along with Ventricular Dysfunction in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Ventricular Dysfunction: A condition in which HEART VENTRICLES exhibit impaired function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, WF | 1 |
| Zoghbi, WA | 1 |
1 review available for dipyridamole and Ventricular Dysfunction
| Article | Year |
|---|---|
Stress echocardiography: current methodology and clinical applications.
Topics: Cell Survival; Coronary Disease; Dipyridamole; Echocardiography, Stress; Echocardiography, Three-Dim | 2005 |